Investment PotentialCantargia is seen as an undervalued, attractive investment opportunity for long-term investors due to its multiple programs and potential value-drivers.

Market OpportunityThere are currently no approved bispecifics in the autoimmune space, providing a significant market opportunity for the company.

Bears Say

Clinical Trial ResultsThe TRIFOUR Phase 2 study in TNBC did not meet its primary ORR endpoint, comparing nadunolimab in combination with chemotherapy vs. chemotherapy alone.

Cantargia AB News

Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating

Analyst Sara Nik of H.C. Wainwright reiterated a Buy rating on Cantargia AB, retaining the price target of...

2d ago

Cantargia AB Releases Interim Report Highlighting Strategic Progress

An announcement from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia AB has released its interim report...

3d ago

Cantargia AB Announces Nomination Committee for 2026 AGM

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia AB has announced the appointment of its Nomination...

10d ago

Cantargia AB to Release Interim Report and Host Investor Presentation

The latest announcement is out from Cantargia AB ( ($SE:CANTA) ). Cantargia AB announced the release of its...

17d ago

Cantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating

Sara Nik, an analyst from H.C. Wainwright, has initiated a new Buy rating on Cantargia AB (7V3). Sara...

24d ago

Cantargia AB to Present at Key Investor Conferences

Cantargia AB ( ($SE:CANTA) ) has provided an update. Cantargia AB announced its participation in upcoming investor conferences,...

29d ago

Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus

Cantargia AB ( ($SE:CANTA) ) has provided an announcement. Cantargia AB has appointed Dr. Wolfram Dempke as its...

2M ago

Cantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million

An announcement from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia AB has completed the sale of...

2M ago

Cantargia Secures US Patent for Nadunolimab, Boosting Market Position

Cantargia AB ( ($SE:CANTA) ) has shared an announcement. Cantargia AB announced that the United States Patent and...

3M ago

Cantargia AB’s Mid-Year Report Highlights Progress in Antibody-Based Drug Development

The latest update is out from Cantargia AB ( ($SE:CANTA) ). Cantargia AB released its interim report for...

3M ago

CANTA FAQ

What was Cantargia AB’s price range in the past 12 months?

Cantargia AB lowest stock price was kr1.00 and its highest was kr4.78 in the past 12 months.

What is Cantargia AB’s market cap?

Cantargia AB’s market cap is kr815.45M.

When is Cantargia AB’s upcoming earnings report date?

Cantargia AB’s upcoming earnings report date is Feb 20, 2026 which is in 91 days.

How were Cantargia AB’s earnings last quarter?

Cantargia AB released its earnings results on Nov 19, 2025. The company reported kr1.07 earnings per share for the quarter, beating the consensus estimate of -kr0.17 by kr1.24.

Is Cantargia AB overvalued?

According to Wall Street analysts Cantargia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cantargia AB pay dividends?

Cantargia AB does not currently pay dividends.

What is Cantargia AB’s EPS estimate?

Cantargia AB’s EPS estimate is -0.19.

How many shares outstanding does Cantargia AB have?

Cantargia AB has 248,611,650 shares outstanding.

What happened to Cantargia AB’s price movement after its last earnings report?

Cantargia AB reported an EPS of kr1.07 in its last earnings report, beating expectations of -kr0.17. Following the earnings report the stock price went down -7.445%.

Which hedge fund is a major shareholder of Cantargia AB?

Currently, no hedge funds are holding shares in SE:CANTA

Company Description

Cantargia AB

Cantargia AB (CANTA) is a biotechnology company based in Sweden, focusing on the research and development of antibody-based treatments for various cancer types and autoimmune diseases. The company utilizes its proprietary technology platform to develop innovative therapies targeting specific molecular pathways involved in disease progression. Cantargia's lead product candidate, nadunolimab (CAN04), is an antibody therapy currently undergoing clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer.